British pharmaceutical company AstraZeneca announced on Monday, October 26 that its vaccine under development against Covid-19 is eliciting an encouraging immune response from young adults and the elderly.
"
It is encouraging to see similar immune responses between the elderly and young adults,
" said a spokesperson for AstraZeneca who is working on the vaccine with the University of Oxford.
"
The results are fueling evidence for the safety and immune response
" of the vaccine, according to the group.
Read also: Covid-19: how states are preparing to vaccinate 7.8 billion people
The University of Oxford specifies that these data come from the first so-called phase 2 clinical trials. The vaccine is currently at the stage of larger so-called phase 3 clinical trials, ie the stage preceding its authorization by the authorities.
The clinical trial has also resumed in the United States, the only country where it was still suspended following the onset of a disease in a participant more than six weeks ago, AstraZeneca announced Friday.
The results of the trial are expected this year for this vaccine project, which is one of the most advanced in the world.
It is one of ten to be tested in tens of thousands of volunteers in a phase 3 trial, with projects from the United States, China and Russia.
Read also: The clinical trial of the AstraZeneca / Oxford vaccine against Covid-19 has resumed in the United States
The pharmaceutical group has pre-sold hundreds of millions of doses on several continents and signed partnerships with other producers so that the doses are produced locally.
The expected demand amounts to billions of doses.
In the United Kingdom, Health Minister Matt Hancock estimated Monday on BBC 4 radio that "
the bulk of the deployment
" of a vaccine against the coronavirus could take place before next summer.
He did not rule out that some people could even receive it before Christmas.
»SEE ALSO -
Covid-19: behind the scenes of the vaccine factory
